A Pre-Phase I Biodistribution Study Of hCC^CH2 Labeled With 131 Iodine In Patients With Gastrointestinal Adenocarcinomas
OBJECTIVES: I. Determine the biodistribution and biokinetics of iodine I 131-labeled
monoclonal antibody CC49-delta CH2 in patients with gastrointestinal adenocarcinoma. II.
Determine the human anti-human monoclonal antibody response in patients treated with this
OUTLINE: Patients receive iodine I 131-labeled monoclonal antibody CC49-delta CH2 (131I MOAB
CC49-delta CH2) IV over 5-10 minutes on day 0. Patients also receive unlabeled monoclonal
antibody CC49-delta CH2 IV over 5 minutes followed by 131I MOAB CC49-delta CH2 IV over 5-10
minutes on day 28. Patients are followed weekly for 4 months and then every 3 months for 1
PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study within 1 year.
Primary Purpose: Treatment
Margaret A. Tempero, MD
University of California, San Francisco
United States: Federal Government
|UCSF Cancer Center and Cancer Research Institute||San Francisco, California 94115-0128|